Barclays maintains an 'Overweight' on ZIOPHARM Oncology (NASDAQ: ZIOP), PT $9.

Barclays analyst says, "We are maintaining our rating on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE